Hyperion DeFi (HYPD) investor relations material

Executive summary

• Achieved record Q1 2026 net income of $8.8M and adjusted EBITDA of $19.5M, reversing prior losses, driven by digital asset gains and DeFi strategies.

• Adjusted Gross Profit grew 17% sequentially to $960K, up 119% since Q3, led by DeFi Monetization and Yield Enhancement strategies.

• Raised full-year 2026 adjusted gross profit guidance by ~20% to $5M–$7M, about 5x 2025 results, citing strong business momentum and successful equity raises.

• Treasury holdings exceeded 2M HYPE, 1.9M KNTQ, and 10M HPL tokens as of May 11, 2026, with rights to 1% of Silhouette equity.

• Management is winding down legacy biotech/ophthalmic operations to focus solely on digital assets and DeFi.

Financial highlights

• Q1 2026 adjusted gross profit: $960K (up from $821K in Q4 and $439K in Q3); net income: $8.8M (vs. Q4 net loss of $39.8M); adjusted EBITDA: $19.5M (vs. Q4 -$38.9M).

• Operating expenses (excluding stock comp): $2.98M in Q1 2026, down 1% QoQ; SG&A: $2.7M, down 5% QoQ.

• Net asset value rose from $44.2M (Q4) to $69.9M (Q1) to ~$90M (May 11); gross HYPE holdings reached $71.0M.

• Cash, cash equivalents, and USDH totaled $9.1M at Q1 end, rising to $16.0M by May 11, 2026.

• Realized and unrealized gains on digital assets totaled $15.3M, offset by a $1.2M impairment loss.

Outlook and guidance

• Full-year 2026 adjusted gross profit guidance raised to $5M–$7M, with cash flow breakeven expected by year-end.

• Anticipates continued growth in DeFi monetization and yield enhancement, with further ecosystem rewards and new partnerships.

• Expects near full wind-down of legacy biotech/ophthalmic operations by Q2, eliminating related expenses.

• Operating expenses excluding stock-based compensation anticipated to fall below $3.0M per quarter starting Q2 2026.

• Existing cash and equivalents expected to fund operations for at least the next 12 months.